Since the beginning of 2011, renowned scholars have been advising Merck on bioethics issues. "At the very first meeting of the Merck Bioethics Advisory Panel, these high-ranking experts offered us completely new perspectives on a number of issues," says Florian Bieber, Chief Medical Officer of Merck and the Chairman of the ethics council.
The panel has only an advisory function and makes no decisions. "The experts on the panel are expected to inform and sensitize us early on concerning bioethics issues that will be coming up in the future," Bieber adds. Innovative medications produced via biotechnology could relieve suffering, but in order to do so they would have to intervene in basic biological processes. Some aspects of this development are giving rise to controversy in a general public discussion.
The members of the panel represent a variety of disciplines and perspectives:
Prof. Jochen Taupitz, University of Mannheim
Professor for Civil Law, Civil Procedure Law, Private International Law, and Comparative Law
Prof. Nikolaus Knoepffler, Friedrich Schiller University of Jena
Director of the Ethics Center, Chair of Applied Ethics
Prof. Christoph Rehmann-Sutter, University of Lübeck
Professor of Theory and Ethics in the Biosciences
Prof. Jeremy Sugarman, Johns Hopkins University, Baltimore (Maryland/USA)
Harvey M. Meyerhoff Professor of Bioethics and Medicine, Professor of Medicine, Professor of Health Policy and Management
Prof. Dena S. Davis, Lehigh University, Bethlehem (Pennsylvania, USA)
Holder of the Presidential Chair in Health /Humanties and social sciences
Prof. Jeanne Loring, Scripps Research Institute, La Jolla (California, USA)
Founding Director of the Center for Regenerative Medicine |